Transanal Total Mesorectal Excision (TaTME) Shows High Local Recurrence-Free Survival in Rectal Cancer Patients

Researchers analyzed local recurrence and disease-free survival in patients treated with transanal total mesorectal excision (TaTME) for rectal cancer. The study included 279 patients treated at a high-volume tertiary center in Vancouver, Canada. The results showed that the local recurrence rate was 4.7%, and the estimated 2-year local recurrence-free survival was 95.0% with 94.5% at 5 years. These findings support the oncologic safety of TaTME and its acceptable outcomes.